G1 Therapeutics Investor Relations Material
Latest events
Study Update
G1 Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from G1 Therapeutics Inc
Access all reports
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company's lead product candidate is trilaciclib (G1T48), which is in Phase 3 clinical trial for use as a chemoprotective agent to mitigate the cardiopulmonary toxicity associated with chemotherapy comprising anthracycline and cyclophosphamide administered in the adjuvant, locally advanced or metastatic setting; and that is in Phase 1b/2 trial for use with carboplatin.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
GTHX
Country
🇺🇸 United States